231 related articles for article (PubMed ID: 31254667)
1. Semisynthetic bile acids: a new therapeutic option for metabolic syndrome.
Lazarević S; Đanić M; Goločorbin-Kon S; Al-Salami H; Mikov M
Pharmacol Res; 2019 Aug; 146():104333. PubMed ID: 31254667
[TBL] [Abstract][Full Text] [Related]
2. Reversal of metabolic disorders by pharmacological activation of bile acid receptors TGR5 and FXR.
Jadhav K; Xu Y; Xu Y; Li Y; Xu J; Zhu Y; Adorini L; Lee YK; Kasumov T; Yin L; Zhang Y
Mol Metab; 2018 Mar; 9():131-140. PubMed ID: 29361497
[TBL] [Abstract][Full Text] [Related]
3. Functional characterization of the semisynthetic bile acid derivative INT-767, a dual farnesoid X receptor and TGR5 agonist.
Rizzo G; Passeri D; De Franco F; Ciaccioli G; Donadio L; Rizzo G; Orlandi S; Sadeghpour B; Wang XX; Jiang T; Levi M; Pruzanski M; Adorini L
Mol Pharmacol; 2010 Oct; 78(4):617-30. PubMed ID: 20631053
[TBL] [Abstract][Full Text] [Related]
4. Semisynthetic bile acid FXR and TGR5 agonists: physicochemical properties, pharmacokinetics, and metabolism in the rat.
Roda A; Pellicciari R; Gioiello A; Neri F; Camborata C; Passeri D; De Franco F; Spinozzi S; Colliva C; Adorini L; Montagnani M; Aldini R
J Pharmacol Exp Ther; 2014 Jul; 350(1):56-68. PubMed ID: 24784847
[TBL] [Abstract][Full Text] [Related]
5. Intestine farnesoid X receptor agonist and the gut microbiota activate G-protein bile acid receptor-1 signaling to improve metabolism.
Pathak P; Xie C; Nichols RG; Ferrell JM; Boehme S; Krausz KW; Patterson AD; Gonzalez FJ; Chiang JYL
Hepatology; 2018 Oct; 68(4):1574-1588. PubMed ID: 29486523
[TBL] [Abstract][Full Text] [Related]
6. New insights in the multiple roles of bile acids and their signaling pathways in metabolic control.
de Boer JF; Bloks VW; Verkade E; Heiner-Fokkema MR; Kuipers F
Curr Opin Lipidol; 2018 Jun; 29(3):194-202. PubMed ID: 29553998
[TBL] [Abstract][Full Text] [Related]
7. Intestinal Farnesoid X Receptor and Takeda G Protein Couple Receptor 5 Signaling in Metabolic Regulation.
Chiang JY; Pathak P; Liu H; Donepudi A; Ferrell J; Boehme S
Dig Dis; 2017; 35(3):241-245. PubMed ID: 28249273
[TBL] [Abstract][Full Text] [Related]
8. Bile acid receptors FXR and TGR5 signaling in fatty liver diseases and therapy.
Chiang JYL; Ferrell JM
Am J Physiol Gastrointest Liver Physiol; 2020 Mar; 318(3):G554-G573. PubMed ID: 31984784
[TBL] [Abstract][Full Text] [Related]
9. The Pharmacology of Bile Acids and Their Receptors.
Fiorucci S; Distrutti E
Handb Exp Pharmacol; 2019; 256():3-18. PubMed ID: 31201555
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological Applications of Bile Acids and Their Derivatives in the Treatment of Metabolic Syndrome.
Ðanić M; Stanimirov B; Pavlović N; Goločorbin-Kon S; Al-Salami H; Stankov K; Mikov M
Front Pharmacol; 2018; 9():1382. PubMed ID: 30559664
[TBL] [Abstract][Full Text] [Related]
11. INT-767 prevents NASH and promotes visceral fat brown adipogenesis and mitochondrial function.
Comeglio P; Cellai I; Mello T; Filippi S; Maneschi E; Corcetto F; Corno C; Sarchielli E; Morelli A; Rapizzi E; Bani D; Guasti D; Vannelli GB; Galli A; Adorini L; Maggi M; Vignozzi L
J Endocrinol; 2018 Aug; 238(2):107-127. PubMed ID: 29945982
[TBL] [Abstract][Full Text] [Related]
12. Investigation on bile acid receptor regulators. Discovery of cholanoic acid derivatives with dual G-protein coupled bile acid receptor 1 (GPBAR1) antagonistic and farnesoid X receptor (FXR) modulatory activity.
Sepe V; Renga B; Festa C; Finamore C; Masullo D; Carino A; Cipriani S; Distrutti E; Fiorucci S; Zampella A
Steroids; 2016 Jan; 105():59-67. PubMed ID: 26607331
[TBL] [Abstract][Full Text] [Related]
13. Bile acids, obesity, and the metabolic syndrome.
Ma H; Patti ME
Best Pract Res Clin Gastroenterol; 2014 Aug; 28(4):573-83. PubMed ID: 25194176
[TBL] [Abstract][Full Text] [Related]
14. A dual agonist of farnesoid X receptor (FXR) and the G protein-coupled receptor TGR5, INT-767, reverses age-related kidney disease in mice.
Wang XX; Luo Y; Wang D; Adorini L; Pruzanski M; Dobrinskikh E; Levi M
J Biol Chem; 2017 Jul; 292(29):12018-12024. PubMed ID: 28596381
[TBL] [Abstract][Full Text] [Related]
15. Metabolic effects of bile acid sequestration: impact on cardiovascular risk factors.
Spinelli V; Chávez-Talavera O; Tailleux A; Staels B
Curr Opin Endocrinol Diabetes Obes; 2016 Apr; 23(2):138-44. PubMed ID: 26859552
[TBL] [Abstract][Full Text] [Related]
16. Bile acid derivatives as ligands of the farnesoid x receptor: molecular determinants for bile acid binding and receptor modulation.
Gioiello A; Cerra B; Mostarda S; Guercini C; Pellicciari R; Macchiarulo A
Curr Top Med Chem; 2014; 14(19):2159-74. PubMed ID: 25388535
[TBL] [Abstract][Full Text] [Related]
17. ENDOCRINOLOGY IN PREGNANCY: Metabolic impact of bile acids in gestation.
Fan HM; Mitchell AL; Williamson C
Eur J Endocrinol; 2021 Mar; 184(3):R69-R83. PubMed ID: 33434155
[TBL] [Abstract][Full Text] [Related]
18. Chemical exploration of TGR5 functional hot-spots: Synthesis and structure-activity relationships of C7- and C23-Substituted cholic acid derivatives.
Rosatelli E; Carotti A; Cerra B; De Franco F; Passeri D; Pellicciari R; Gioiello A
Eur J Med Chem; 2023 Dec; 261():115851. PubMed ID: 37813065
[TBL] [Abstract][Full Text] [Related]
19. Gluco-Metabolic Effects of Pharmacotherapy-Induced Modulation of Bile Acid Physiology.
Brønden A; Knop FK
J Clin Endocrinol Metab; 2020 Jan; 105(1):. PubMed ID: 31630179
[TBL] [Abstract][Full Text] [Related]
20. SAR studies on FXR modulators led to the discovery of the first combined FXR antagonistic/TGR5 agonistic compound.
Lamers C; Merk D; Gabler M; Flesch D; Kaiser A; Schubert-Zsilavecz M
Future Med Chem; 2016; 8(2):133-48. PubMed ID: 26824277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
